- Home
- PAXS vs CSTL Comparison
PAXS vs CSTL Comparison
Compare PAXS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- CSTL
- Stock Information
- Founded
- PAXS 2021
- CSTL 2007
- Country
- PAXS United States
- CSTL United States
- Employees
- PAXS N/A
- CSTL N/A
- Industry
- PAXS Investment Managers
- CSTL Medical Specialities
- Sector
- PAXS Finance
- CSTL Health Care
- Exchange
- PAXS Nasdaq
- CSTL Nasdaq
- Market Cap
- PAXS 710.4M
- CSTL 661.7M
- IPO Year
- PAXS N/A
- CSTL 2019
- Fundamental
- Price
- PAXS $15.94
- CSTL $40.12
- Analyst Decision
- PAXS
- CSTL Strong Buy
- Analyst Count
- PAXS 0
- CSTL 6
- Target Price
- PAXS N/A
- CSTL $38.67
- AVG Volume (30 Days)
- PAXS 195.0K
- CSTL 590.2K
- Earning Date
- PAXS 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- PAXS 11.72%
- CSTL N/A
- EPS Growth
- PAXS N/A
- CSTL N/A
- EPS
- PAXS N/A
- CSTL N/A
- Revenue
- PAXS N/A
- CSTL $343,530,000.00
- Revenue This Year
- PAXS N/A
- CSTL N/A
- Revenue Next Year
- PAXS N/A
- CSTL N/A
- P/E Ratio
- PAXS N/A
- CSTL N/A
- Revenue Growth
- PAXS N/A
- CSTL 10.15
- 52 Week Low
- PAXS $12.57
- CSTL $14.59
- 52 Week High
- PAXS $15.93
- CSTL $40.51
- Technical
- Relative Strength Index (RSI)
- PAXS 55.81
- CSTL 84.06
- Support Level
- PAXS $15.36
- CSTL $33.03
- Resistance Level
- PAXS $15.71
- CSTL $35.49
- Average True Range (ATR)
- PAXS 0.24
- CSTL 1.57
- MACD
- PAXS 0.02
- CSTL 0.41
- Stochastic Oscillator
- PAXS 73.96
- CSTL 93.50
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.